NCT01617226 - Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

December 31, 2020

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

Azacitidine

Azacitidine both arms; 75mg/m\^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.

DRUG

Vorinostat

Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.

Trial Locations (13)

Barts and the London NHS Trust, London

King's College Hospital, London

Hammersmith Hospital, London

The Christie Hospital, Manchester

Royal Liverpool University Hospital, Liverpool

Belfast City Hospital, Belfast

Nottingham University Hospitals NHS Trust, Nottingham

Oxford University Hospitals NHS Trust, Oxford

University Hospital of Wales, Cardiff

Queen Elizabeth Hospital, Birmingham

St James's University Hospital, Leeds

Beatson West of Scotland Cancer Centre, Glasgow

Southampton General Hospital, Southampton